TABLE 4.
Results of acute toxicity analysisa
| Compound | Result after treatment at the following dose (mg/kg): |
NOAEL (mg/kg) | |||||
|---|---|---|---|---|---|---|---|
| 0 | 12.5 | 25 | 50 | 100 | 200 | ||
| 35DAP073 | NDE | NDE | NDE | Loss of mouse body wt | Tremors, ataxia | Death | 25 |
| 35DAP081 | NDE | Ataxia, tremors, excitation and vocalizationb | Ataxia, tremors, excitation and vocalizationb | Ataxia, tremors, excitation and vocalizationb | Ataxia, tremors, excitation and vocalizationb | Ataxia, tremors, excitation and vocalizationb | <12. 5 |
Escalating doses starting at 12.5 mg/kg and increasing to 200 mg/kg were administered i.p. in a 0.1-ml final volume to female Swiss Webster mice, using a single mouse per dose. NOAEL, no-observed-adverse-effect level (for noninvasive parameters); NDE, no detectable effect.
These effects were observed after 2 h of compound administration.